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ABSTRACT 
 
Objective: To evaluate and compare the performance of routine ultrasonographic estimated fetal 
weight (EFW) and fetal abdominal circumference (AC) at 31+0 - 33+6 and 35+0 - 36+6 weeks’ 
gestation in the prediction of small for gestational age (SGA) neonates. 
 
Methods: This was a prospective study of 21,989 singleton pregnancies that had undergone 
routine ultrasound examination at 31+0 - 33+6 weeks’ gestation and 45,847 that had undergone 
routine ultrasound examination at 35+0 - 36+6 weeks’ gestation. In each case the estimated fetal 
weight (EFW) from measurements of fetal head circumference (HC), AC and femur length (FL) 
was calculated by the Hadlock formula and this was expressed as percentile according to the 
Fetal Medicine Foundation fetal and neonatal population weight charts. The same charts were 
used for defining SGA neonates with birthweight <10th and <3rd percentiles. For each gestational 
window the screen positive and detection rate, at different EFW percentile cut-offs between the 
10th and 50th percentile, were calculated for prediction of delivery of SGA neonates with 
birthweight <10th and <3rd percentiles within two weeks and at any stage after assessment. The 
areas under the receiver operating characteristics curve (AUROC) of screening for SGA neonates 
by EFW and AC at 31+0 - 33+6 and at 35+0 - 36+6 weeks’ gestation were compared. 
 
Results: First, the AUROCs of screening by EFW for SGA neonates with birthweight <10th and 
<3rd percentiles within two weeks and at any stage after screening at 35+0 - 36+6 weeks’ gestation 
were significantly higher than those at 31+0 - 33+6 weeks (p<0.001). Second, at both 35+0 - 36+6 
and 31+0 - 33+6 weeks’ gestation, the predictive performance for SGA neonates with birthweight 
<10th and <3rd percentiles born at any stage after screening was significantly higher with EFW Z-
score than AC Z-score. Similarly, at 35+0 - 36+6 weeks, but not at 31+0 - 33+6 weeks, the predictive 
performance for SGA neonates with birthweight <10th and <3rd percentiles born within two weeks 
of screening was significantly higher with EFW Z-score than AC Z-score. Third, screening by EFW 
<10th percentile at 35+0 - 36+6 weeks’ gestation predicted 70% and 84% of neonates with 
birthweight <10th and <3rd percentiles born within two weeks after assessment and the respective 
values for neonates born at any stage after assessment were 46% and 65%. Fourth, prediction 
of >85% of SGA neonates with birthweight <10th percentile born at any stage after screening at 
35+0 - 36+6 weeks’ gestation requires use of EFW <40th percentile. Screening at this percentile cut-
off predicted 95% and 99% of neonates with birthweight <10th and <3rd percentiles born within two 
weeks after assessment and the respective values for neonates born at any stage after 
assessment were 88% and 94%.  
 
Conclusion: The predictive performance for SGA neonates by routine ultrasonographic 
examination during the third trimester is higher if first, the scan is carried out at 35+0 - 36+6 weeks’ 
gestation than at 31+0 - 33+6 weeks; second, the method of screening is EFW than fetal AC; third, 
the outcome measure is birthweight <3rd than <10th percentile; and fourth, if delivery occurs within 
two weeks than at any stage after assessment. Prediction of SGA neonates by EFW <10th 
percentile is modest and prediction of >85% of cases at 35+0 - 36+6 weeks’ gestation necessitates 
use of EFW <40th percentile.  
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INTRODUCTION 
 
National guidelines from many developed countries define fetal growth restriction on the basis of 
ultrasonographic estimated fetal weight (EFW) or fetal abdominal circumference (AC) <10th 
percentile and severe growth restriction as EFW <3rd percentile.1 There are also extensive reports 
on how best to manage pregnancies with small for gestational age (SGA) fetuses,1,2 However, 
there is uncertainty as to the best approach for identifying such SGA fetuses, because of first, the 
existence of a wide range of charts for fetal size and birthweight, second, the controversy of 
universal versus selective ultrasound examination based on maternal risk factors and the results 
of abdominal palpation or serial measurements of symphysial-fundal height, third, lack of 
consistent data on the performance of EFW versus AC for prediction of SGA neonates, and fourth, 
limited data on the best time for a universal third trimester scan at 32 versus 36 weeks’ gestation.  
 
We have addressed the issue of inconsistency between fetal and neonatal growth charts by 
developing EFW and birthweight reference ranges with a common median.3 Previous studies 
provided evidence that the predictive performance of the traditional method of identifying 
pregnancies with SGA fetuses by maternal abdominal palpation and serial measurements of 
symphysial-fundal height is poor.4,5 There is some evidence that improved prediction of SGA is 
achieved by universal sonographic fetal biometry during the third trimester; a study in 3,977 
nulliparous women, reported that universal third trimester ultrasonography tripled the detection of 
SGA neonates compared to selective ultrasonography based on maternal risk factors and the 
results of measurements of symphysial-fundal height.6 A recent systematic review and meta-
analysis of 21 prospective and retrospective cohort studies in low-risk or non-selected singleton 
pregnancies with screening ultrasound performed at ≥32 weeks’ gestation reported that the 
predictive performance for SGA neonates of fetal AC and EFW was similar.7 However, a study of 
5,163 singleton pregnancies with fetal biometry at 22-43 weeks’ gestation and livebirth of 
phenotypically normal neonates within two days of the ultrasound examination reported that the 
most accurate formula for prediction of birthweight, among 70 models identified by systematic 
review of 45 studies, was that of Hadlock et al.,8 which incorporated measurements of head 
circumference (HC), AC and femur length (FL).9 As for the issue of timing of the third trimester 
scan there is some evidence that the predictive performance of a scan at 36 weeks may be 
superior to that at 32 weeks; a randomized study in 2,586 low-risk singleton pregnancies reported 
that the predictive performance for SGA neonates <10th and <3rd percentiles was superior at 36 
compared to 32 weeks’ gestation.10 
 
The objective of this study is to evaluate and compare the performance of routine 
ultrasonographic EFW and fetal AC at 31+0 - 33+6 and 35+0 - 36+6 weeks’ gestation in the prediction 
of SGA neonates born within two weeks and at any stage after assessment. 
 
METHODS 
 
This was a prospective study of 21,989 singleton pregnancies that had undergone routine 
ultrasound examination at 31+0 - 33+6 weeks’ gestation and 45,847 that had undergone routine 
ultrasound examination at 35+0 - 36+6 weeks’ gestation at King’s College Hospital, London or 
Medway Maritime Hospital, Gillingham, UK. In the participating hospitals all women with singleton 
pregnancies are offered routine ultrasound examinations at 11+0 - 13+6 and at 19+0 to 23+6 weeks’ 
gestation. During a period (May 2011 to March 2014) an additional scan was offered at 31+0 to 
33+6 weeks, but subsequently (March 2014 and September 2018) this was changed to 35+0 to 
36+6 weeks. In the selection of patients care was taken to include routine scans and not follow-up 
scans for maternal medical conditions or a suspected problem in fetal growth.  
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In the first or second trimester visit we recorded maternal demographic characteristics and 
medical history and in the third trimester visits we carried out an ultrasound examination for fetal 
anatomy and measurement of fetal HC, AC and FL for calculation of EFW using the formula by 
Hadlock et al.8 Gestational age was determined by the measurement of fetal crown-rump length 
at 11-14 weeks or the fetal head circumference at 19-24 weeks.11,12 The ultrasound examinations 
were carried out by examiners who had obtained the Fetal Medicine Foundation certificate of 
competence in ultrasound examination for fetal abnormalities. Data from the patients included in 
this study were the subject of previous publications.13-17 
 
The women gave written informed consent to participate in the study, which was approved by the 
NHS Research Ethics Committee. The inclusion criteria for this study were singleton pregnancies 
examined at 31+0 - 33+6 or 35+0 - 36+6 weeks’ gestation and delivering a non-malformed live birth 
or stillbirth. We excluded pregnancies with aneuploidies and major fetal abnormalities.  
 
Patient characteristics  
 
Patient characteristics recorded included maternal age, racial origin (White, Black, South Asian, 
East Asian and mixed), method of conception (natural, in vitro fertilization or use of ovulation 
induction drugs), cigarette smoking during pregnancy, medical history of chronic hypertension and 
diabetes mellitus, obstetric history including parity (parous or nulliparous if no previous 
pregnancies at > 24 weeks’ gestation), and previous pregnancy with SGA. The maternal weight 
and height were measured. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the general 
medical practitioners of the women. The outcome measures of the study were birth of a neonate 
with birthweight <10th or <3rd percentile for gestational age at delivery.3  
 
Statistical analysis 
 
Data were expressed as median (interquartile range [IQR]) for continuous variables and n (%) for 
categorical variables. Mann-Whitney U-test and χ2-square test or Fisher’s exact test, were used 
for comparing outcome groups for continuous and categorical data, respectively. Significance was 
assumed at 5%. 
 
The observed measurements of EFW and birthweight were converted to Z-scores and percentiles 
adjusted for gestational age according to the Fetal Medicine Foundation fetal and neonatal 
population weight charts.3 Similarly AC was converted to Z-scores and percentiles adjusted for 
gestational age according to the reference ranges of Snijders and Nicolaides.12 Logistic 
regression analysis was undertaken to determine the significance of contribution of AC and EFW 
Z-score in prediction of delivery of SGA neonates <10th and <3rd percentile. The performance of 
screening was determined by receiver operating characteristic (ROC) curves and the areas under 
the ROC curves (AUROC) of screening at 31+0 - 33+6 and 35+0 - 36+6 weeks’ gestation in the 
prediction of SGA neonates were compared.18 For each gestational window the screen positive 
and detection rate, at different EFW percentile cut-offs between the 10th and 50th percentile, were 
calculated for prediction of delivery of SGA neonates with birthweight <10th and <3rd percentiles 
within two weeks and at any stage after assessment.  
 
The statistical software package SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0, 
Armonk, NY: IBM Corp; 2016) and Medcalc (Medcalc Software, Mariakerke, Belgium) were used 
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for data analyses. 
 
RESULTS 
 
Patient characteristics 
 
The characteristics of the study population are shown in Table 1. The characteristics of those with 
a scan at 31+0 - 33+6 weeks’ gestation were similar to those with a scan at 35+0 - 36+6 weeks. In 
both study periods in the group of neonates with birthweight <10th percentile, compared to those 
with birthweight ≥10th percentile, the median maternal age, weight and height, EFW Z-score, AC 
Z-score, birthweight Z-score and gestational age at delivery were lower, more women were of 
non-White racial origin, were smokers, were parous with previous affected pregnancy by SGA, 
and less women were parous without previous SGA. 
 
Delivery within two weeks of the ultrasound examination at 31+0 - 33+6 weeks’ gestation occurred 
in 234 (1.1%) of the 21,989 pregnancies. These included 143 (61.1%) that delivered after 
spontaneous onset of labor and 91 (38.9%) that delivered after induction of labor or elective 
cesarean section. The indications for iatrogenic delivery were: (a) severe preeclampsia and / or 
fetal growth restriction (78.0%); (b) antepartum hemorrhage due to placenta previa or abruption 
(11.0%); (c) non-SGA fetuses with abnormal fetal Doppler, abnormal fetal heart rate pattern or 
reduced fetal movements (4.4%); (d) fetal death (2.2%); (e) fetal anemia (2.2%), (f) obstetric 
cholestasis (1.1%), (g) maternal pneumonia (1.1%). 
 
Delivery within two weeks of the ultrasound examination at 35+0 - 36+6 weeks’ gestation occurred 
in 5,342 (11.7%) of the 45,847 pregnancies. These included 2,988 (55.9%) that delivered after 
spontaneous onset of labor and 2,354 (44.1%) that delivered after induction of labor or elective 
cesarean section. The indications for iatrogenic delivery were: (a) chronic hypertension, 
preeclampsia, gestational hypertension, diabetes mellitus, gestational diabetes or obstetric 
cholestasis (40.1%); (b) other maternal medical condition or maternal request (6.1%); (c) SGA 
fetuses with or without abnormal fetal Doppler findings (23.8%); (d) non-SGA fetuses with 
abnormal fetal Doppler or fetal heart rate pattern, reduced fetal movements or oligohydramnios 
(6.1%); (e) previous cesarean section or myomectomy (8.8%); (f) antepartum hemorrhage due to 
placenta previa or abruption (5.6%); (g) breech or transverse lie (4.7%); (h) previous stillbirth or 
other adverse perinatal outcome (2.2%); (i) polyhydramnios and / or large for gestational age 
(2.1%); (j) fetal death (0.5%). 
 
Performance of screening for SGA neonates  
 
Screening at 35+0 - 36+6 versus 31+0 - 33+6 weeks’ gestation  
 
The AUROCs of screening by EFW for SGA neonates with birthweight <10th percentile within two 
weeks and at any stage after screening at 35+0 - 36+6 weeks’ gestation (0.933; 95% CI 0.926 - 
0.941 and 0.833; 95% CI 0.879 - 0.888) were significantly higher than those at 31+0 - 33+6 weeks 
(0.906; 95% CI 0.870 - 0.942; p<0.001 and 0.822; 95% CI 0.814 - 0.830; p<0.001) (Table 2; Figure 
1). Similarly, the AUROCs of screening by EFW for SGA neonates with birthweight <3rd percentile 
within two weeks and at any stage after screening at 35+0 - 36+6 weeks’ gestation (0.945; 95% CI 
0.937 - 0.952 and 0.918; 95% CI 0.912 - 0.923) were significantly higher than those at 31+0 - 33+6 
weeks (0.897; 95% CI 0.857 - 0.937; p=0.034 and 0.858; 95% CI 0.847 - 0.869; p<0.001) (Table 
2, Figure 2). 
 
Screening by EFW versus fetal AC  
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Comparisons of the AUROC in screening for SGA neonates by EFW and AC are shown in Table 
2 and Figures 1 and 2. At both 35+0 - 36+6 and 31+0 - 33+6 weeks’ gestation, the predictive 
performance for SGA neonates with birthweight <10th and <3rd percentiles born at any stage after 
screening was significantly higher with EFW Z-score than AC Z-score. Similarly, at 35+0 - 36+6 
weeks, but not at 31+0 - 33+6 weeks, the predictive performance for SGA neonates with birthweight 
<10th and <3rd percentiles born within two weeks of screening was significantly higher with EFW 
Z-score than AC Z-score.  
 
Screening at different EFW percentile cut-offs  
 
The predictive performance for SGA neonates with birthweight <10th percentile in screening by EFW 
at a series of cut-offs between the 10th and 50th percentile at 35+0 to 36+6 and 31+0 to 33+6 weeks’ 
gestation is shown in Table 3; the respective values for SGA neonates with birthweight <3rd  percentile 
are shown in Table 4. Screening by EFW <10th percentile at 35+0 - 36+6 weeks’ gestation predicted 
70% and 84% of neonates with birthweight <10th and <3rd percentiles born within two weeks after 
assessment and the respective values for neonates born at any stage after assessment were 
46% and 65%.  
 
Prediction of >85% of SGA neonates with birthweight <10th percentile born at any stage after 
screening at 35+0 - 36+6 weeks’ gestation requires use of EFW <40th percentile. Screening at this 
percentile cut-off predicted 95% and 99% of neonates with birthweight <10th and <3rd percentiles 
born within two weeks after assessment and the respective values for neonates born at any stage 
after assessment were 88% and 94%.  
 
DISCUSSION 
 
Main findings of the study 
 
The findings of this study demonstrate that the predictive performance for SGA neonates by 
routine ultrasonographic examination during the third trimester is higher if first, the scan is carried 
out at 35+0 - 36+6 weeks’ gestation than at 31+0 - 33+6 weeks; second, the method of screening is 
EFW than fetal AC; third, the outcome measure is birthweight <3rd than <10th percentile; and 
fourth, if delivery occurs within two weeks than at any stage after assessment. Prediction of SGA 
neonates by EFW <10th percentile is modest and prediction of >85% of cases at 35+0 - 36+6 weeks’ 
gestation necessitates use of EFW <40th percentile.  
 
For SGA neonates born within two weeks of assessment at 31+0 - 33+6 weeks’ gestation there was 
no significant difference in predictive performance between EFW and fetal AC. This is not 
surprising because in about 30% of the babies born within two weeks of assessment there was 
iatrogenic delivery because of severe preeclampsia and / or fetal growth restriction and in such 
cases the fetal AC would be affected more than the HC and FL. In contrast, at 35+0 - 36+6 weeks’ 
gestation in only about 10% of the babies born within two weeks of assessment there was 
iatrogenic delivery for fetal growth restriction. 
 
Screening by EFW <10th percentile at 35+0 - 36+6 weeks’ gestation predicted 70% and 84% of 
neonates with birthweight <10th and <3rd percentiles born within two weeks of assessment with 
positive predictive values of 19.6 and 13.0, respectively. The respective values for neonates born 
at any stage after assessment were 46%, 65%, 59.1 and 31.8. Screening by EFW <40th percentile 
predicted 95% and 99% of neonates with birthweight <10th and <3rd percentiles born within two 
weeks after assessment with positive predictive values of 6.5 and 3.7, respectively; the respective 
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values for neonates born at any stage after assessment were 88%, 94%, 27.3 and 11.2.  
 
Comparison with findings from previous studies 
 
We found that the predictive performance for SGA neonates of EFW is superior to that of fetal 
AC. This finding is consistent with the results of a study that investigated the ability of 
ultrasonographic fetal biometry to predict birthweight in neonates born within two days of the 
ultrasound examination and reported that models incorporating measurements of fetal HC, AC 
and FL were superior to those using AC alone or AC and FL.9 Our findings that the predictive 
performance for SGA neonates by fetal biometry at 35+0 - 36+6 weeks’ gestation is superior to that 
at 31+0 - 33+6 weeks is consistent with the results of a previous study in 2,288 pregnancies 
undergoing ultrasound examination in both of these gestational windows19 and those of a 
randomized trial comparing the performance of ultrasound examination at 36 vs. 32 weeks' 
gestation.10 
 
Implications for clinical practice 
 
Justification of prenatal screening for SGA fetuses is based on first, evidence that such fetuses 
are at increased risk of stillbirth and adverse perinatal outcome,20-23 and second, the expectation 
that these risks can be reduced by medical interventions, such as early delivery.1 In this respect, 
all pregnant women should be offered a routine third trimester scan because such policy is more 
effective in identifying SGA fetuses than selective ultrasonography based on maternal risk factors 
and the results of measurements of symphysial-fundal height.6  
 
Since 85% of SGA neonates are born at term17 and the predictive performance for SGA neonates 
is highest if the scan is carried out close to the time of birth the best time for a routine scan is 
about 36 weeks’ gestation. Identification of SGA fetuses born before 36 weeks’ gestation would 
require ultrasound scans at 26-28 and 30-32 weeks and we have previously proposed that 
selection of the subgroup of the population requiring such additional scans should be based on 
stratification of risks at 20 weeks’ gestation. 24 In relation to SGA born <32 weeks’ gestation, there 
is evidence of a high association with preeclampsia and that the risk can be reduced by first 
trimester screening for preeclampsia and treatment of the high-risk group with aspirin.25-30  
 
The findings of this study highlight that a routine third trimester ultrasound scan constitutes a 
screening rather than diagnostic test for SGA neonates and that the EFW cut-off of the 40th rather 
than the 10th percentile should be used to identify a group in need of further investigations. 
However, only about one in four of such fetuses would actually be SGA at birth and the objective 
of further investigations would be to distinguish between true and false positives. Such an 
objective could potentially be achieved by serial ultrasound scans to define subsequent growth 
and wellbeing; supportive evidence for such expectation is that the predictive performance for 
SGA neonates is considerably higher in pregnancies delivering within two weeks of assessment 
than in those with a longer interval. Alternative strategies, including addition of fetal growth velocity 
between 20 or 32 and 36 weeks’ gestation and addition of maternal risk factors, serum placental 
growth factor, uterine artery pulsatility index and the cerebroplacental ratio, had limited success 
in improving the predictive performance for SGA neonates of EFW at 36 weeks.15-17,31,32  
 
Strengths and limitations of the study 
 
The strengths of this screening study for SGA neonates are first, examination of a large population 
of pregnant women attending for routine assessment of fetal growth and wellbeing at either 31+0 
- 33+6  or 35+0 - 36+6 weeks’ gestation, second, trained sonographers that carried out fetal biometry 
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according to a standardized protocol and use of a widely used model for calculation of EFW 8 
which has been shown to be the most accurate one among 70 previously reported models,9 third, 
use of the Fetal Medicine Foundation fetal and neonatal references ranges which have a common 
median,3 and fourth, direct comparison of the predictive performance of EFW and fetal AC. 
 
A limitation of the study, in relation to the comparison of predictive performance for SGA neonates 
of the scan at 31+0 - 33+6  vs. that at 35+0 - 36+6 weeks’ gestation, is that this was not a randomized 
study. However, the findings are valid because during the two consecutive periods of study the 
characteristics of the population were similar, the two hospitals were the same and the 
ultrasonographers carrying out the scans had received the same training and followed the same 
protocol for conducting the scan.  
 
Conclusions 
 
The predictive performance for SGA neonates by routine ultrasonographic examination during the 
third trimester is higher if the scan is carried out at 35+0 - 36+6 weeks’ gestation than at 31+0 - 33+6 
weeks, but prediction of SGA neonates by EFW <10th percentile is modest and prediction of >85% 
of cases at 35+0 - 36+6 weeks necessitates use of EFW <40th percentile for selecting the group in 
need of further assessment. Future studies will investigate potential methods for reducing the false 
positive rate in the group with EFW <40th percentile. 
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FIGURE LEGENDS 
 
Figure 1. Receiver operating characteristics curves of estimated fetal weight (red curve) and 
abdominal circumference (black curve) at 35+0 - 36+6 weeks’ gestation (solid lines) and at 31+0 - 
33+6 weeks (interrupted lines), in the prediction of small for gestational age neonates with 
birthweight below the 10th percentile delivering within two weeks (left) and at any time (right) from 
assessment. 
 
Figure 2. Receiver operating characteristics curves of estimated fetal weight (red curve) and 
abdominal circumference (black curve) at 35+0 - 36+6 weeks’ gestation (solid lines) and at 31+0 - 
33+6 weeks (interrupted lines), in the prediction of small for gestational age neonates with 
birthweight below the 3rd percentile delivering within two weeks (left) and at any time (right) from 
assessment. 
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Table 1. Maternal and pregnancy characteristics of the study populations. 
 
GA = gestational age; EFW = estimated fetal weight; IQR = interquartile range; SGA = small for gestational age; PE = preeclampsia. 
Characteristic 
Screening at 31+0 - 33+6 weeks Screening at 35+0 - 36+6 weeks 
BW ≥10th percentile 
(n=19,190) 
BW <10th percentile 
(n=2,799) 
BW ≥10th percentile 
(n=40,567) 
BW <10th percentile 
(n=5,280) 
Maternal age in years, median (IQR) 30.7 (26.1, 34.5) 29.8 (24.9, 34.2)** 31.7 (27.4, 35.4) 30.9 (26.2, 35.0)** 
Maternal weight in Kg, median (IQR) 77.1 (69.0, 88.0) 72.0 (64.0, 81.8)** 79.9 (71.5, 91.0) 73.4 (65.5, 83.2)** 
Maternal height in cm, median (IQR) 165 (160, 169) 163 (158, 167)** 165 (161, 170) 163 (158, 167)** 
Racial origin     
   White, n (%) 13,789 (71.9) 1,635 (58.4) 30,812 (76.0) 3,348 (63.4)** 
   Black, n (%) 3,864 (20.1) 799 (28.5)** 6,065 (15.0) 1,131 (21.4)** 
   South Asian, n (%) 732 (3.8) 212 (7.6)** 1,697 (4.2) 488 (9.2)** 
   East Asian, n (%) 388 (2.0) 66 (2.4) 813 (2.0) 126 (2.4) 
   Mixed, n (%) 417 (2.2) 87 (3.1)* 1,180 (2.9) 187 (3.5)* 
Cigarette smoker, n (%) 1,860 (9.7) 527 (18.8)** 2,961 (7.3) 762 (14.4)** 
Conception     
   Natural, n (%) 18,645 (97.2) 2,717 (97.1) 39,190 (96.6) 5,080 (96.2) 
   Ovulation drugs, n (%) 162 (0.8) 24 (0.9) 223 (0.5) 34 (0.6) 
   In vitro fertilization, n (%) 383 (2.0) 58 (2.1) 1,154 (2.8) 166 (3.1) 
Medical conditions     
   Chronic hypertension, n (%) 240 (1.3) 66 (2.4)** 490 (1.2) 90 (1.7)* 
   Diabetes mellitus type 1, n (%) 77 (0.4) 5 (0.2) 162 (0.4) 5 (0.1)* 
   Diabetes mellitus type 2, n (%) 112 (0.6) 23 (0.8) 189 (0.5) 19 (0.4) 
Past obstetric history     
   Nulliparous, n (%) 8,978 (46.8) 1,062 (57.2) 17,911 (44.2) 2,949 (55.9) 
   Parous with prior SGA, n (%) 1,167 (6.1) 434 (15.5)** 3,112 (7.7) 964 (18.3)** 
   Parous without prior SGA, n (%) 9,045 (47.1) 763 (27.3)** 19,544 (48.2) 1,367 (25.9)** 
GA at screening, median (IQR)  32.2 (32.0, 32.6) 32.2 (32.0, 32.6) 36.1 (35.9, 36.4) 36.1 (35.9, 36.4) 
EFW Z-score, median (IQR) 0.02 (-0.63, 0.66) -1.18 (-1.79, -0.59)** 0.01 (-0.59, 0.60) -1.39 (-2.08, -0.85)** 
AC Z-score, median (IQR) -0.05 (-0.48, 0.42) -0.76 (-1.15, -0.35) 0.00 (-0.47, 0.49) -1.02 (-1.49, -0.57)** 
GA at delivery in weeks, median (IQR) 40.4 (39.0, 40.9) 39.5 (38.2, 40.5)** 40.0 (39.1, 40.9) 39.4 (38.2, 40.3)** 
Birthweight Z-score, median (IQR) 0.09 (-0.49, 0.72) -1.76 (-2.20, -1.48)** 0.13 (-0.45, 0.75) -1.72 (-2.14, -1.48)** 
Birthweight in grams, median (IQR) 3470 (3200, 3770) 2710 (2460, 2870)** 3490 (3220, 3790) 2715 (2510, 2860)** 
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Table 2. Comparisons of areas under the curve (95% confidence interval) in screening for SGA neonates by estimated fetal weight and 
fetal abdominal circumference. 
 
Outcome measure 
Delivery within two weeks of screening Delivery at any time after screening 
Estimated fetal 
weight 
Abdominal 
circumference 
P value 
Estimated fetal 
weight 
Abdominal 
circumference 
P value 
35+0 - 36+6 weeks       
  BW <10th percentile 0.933 (0.926 - 0.941) 0.915 (0.906 - 0.924) P<0.001 0.883 (0.879 - 0.888) 0.860 (0.854 - 0.865) P<0.001 
  BW <3rd percentile 0.945 (0.937 - 0.952) 0.930 (0.920 - 0.939) P<0.001 0.918 (0.912 - 0.923) 0.898 (0.891 - 0.905) P<0.001 
31+0 - 33+6 weeks       
  BW <10th percentile 0.906 (0.870 - 0.942) 0.895 (0.849 - 0.931) P=0.256 0.822 (0.814 - 0.830) 0.795 (0.790 - 0.801) P<0.001 
  BW <3rd percentile 0.897 (0.857 - 0.937) 0.892 (0.850 - 0.934) P=0.607 0.858 (0.847 - 0.869) 0.831 (0.819 - 0.842) P<0.001 
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Table 3. Predictive performance for small for gestational age neonates with birthweight <10th percentile in screening by estimated fetal weight 
below specific percentile cut-offs at 35+0 to 36+6 and 31+0 to 33+6 weeks’ gestation. 
 
 
CI = confidence interval; EFW = estimated fetal weight.  
  
EFW cut-off Screen positive rate 
Birth at ≤ 2 weeks from assessment Birth at any time from assessment 
Detection rate 
 
Positive predictive 
value  
Detection rate 
 
Positive predictive 
value 
35+0 to 36+6 weeks n/45,847 (%; 95% CI) n/1,156 (%; 95% CI) % (95% CI) n/5,280 (%; 95% CI) % (95% CI) 
<10th percentile 4,109 (9.0; 8.7-9.3) 804 (70; 67-72) 19.6 (17.4-21.3) 2,429 (46; 45-47) 59.1 (57.6-61.2) 
<15th percentile 6,125 (13.4; 13.1-13.7) 883 (76; 74-79) 14.4 (12.1-16.7) 3,034 (58; 56-59) 49.5 (47.7-51.3) 
<20th percentile 8,089 (17.6; 17.3-17.9) 952 (82; 80-85) 11.8 (9.7-13.4) 3,483 (66; 65-67) 43.1 (41.5-45.6) 
<25th percentile 10,215 (22.3; 22.0-22.6) 1,004 (87; 85-89) 9.8 (7.6-11.8) 3,888 (74; 72-75) 38.1 (36.3-40.5) 
<30th percentile 12,402 (27.1; 26.8-27.4) 1,044 (90; 89-92) 8.4 (6.5-10.2) 4,192 (79; 78-81) 33.8 (31.6-35.7) 
<35th percentile 14,694 (32.1; 31.8-32.4) 1,079 (93; 92-95) 7.3 (5.3-9.5) 4,436 (84; 83-85) 30.2 (28.4-32.5) 
<40th percentile 16,918 (36.9; 36.6-37.2) 1,101 (95; 94-96) 6.5 (4.4-8.7) 4,619 (88; 87-88) 27.3 (25.8-29.6) 
<45th percentile 19,221 (41.9; 41.6-42.2) 1,120 (97; 96-98) 5.8 (3.6-7.8) 4,797 (91; 90-92) 25.0 (23.1-27.0) 
<50th percentile 21,536 (47.0; 46.7-47.3) 1,127 (98; 97-98) 5.2 (3.3-7.5) 4,926 (93; 93-94) 22.9 (21.8-24.6) 
      
31+0 to 33+6 weeks n/21,989 (%, 95% CI) n/93 (%, 95% CI) % (95% CI) n/2,799 (%, 95% CI) % (95% CI) 
<10th percentile 2,164 (9.8; 9.4-10.2) 72 (77; 69-86) 3.3 (2.6-4.0) 1,072 (38; 36-40) 49.5 (47.6-51.4) 
<15th percentile 3,306 (15.0; 14.6-15.4) 79 (85; 78-92) 2.4 (1.8-3.0) 1,408 (50; 48-53) 42.6 (40.8-44.4) 
<20th percentile 4,459 (20.3; 19.9-20.7) 83 (89; 83-96) 1.9 (1.3-2.5) 1,638 (59; 56-61) 36.7 (34.9-38.5) 
<25th percentile 5,578 (25.4; 25.0-25.8) 87 (94; 89-98) 1.6 (1.0-2.2) 1,855 (66; 64-68) 33.3 (31.6-35.1) 
<30th percentile 6,667 (30.3; 29.9-30.7) 88 (95; 90-98) 1.3 (0.7-1.9) 2,032 (73; 71-75) 30.5 (28.8-32.2) 
<35th percentile 7,773 (35.3; 34.9-35.7) 90 (97; 92-99) 1.2 (0.6-1.8) 2,177 (78; 76-80) 28.0 (26.3-29.7) 
<40th percentile 8,842 (40.2; 38.8-40.6) 92 (99; 95-100) 1.0 (0.5-1.6) 2,295 (82; 80-84) 26.0 (24.4-27.6) 
<45th percentile 9,940 (45.2; 44.8-45.6) 92 (99; 95-100) 0.9 (0.4-1.3) 2,396 (86; 84-87) 24.1 (22.5-25.7) 
<50th percentile 11,035 (50.2; 49.8-50.6) 93 (100; 96-100) 0.8 (0.3-1.1) 2,485 (89; 87-89) 22.5 (20.9-24.1) 
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Table 4. Predictive performance for small for gestational age neonates <3rd percentile in screening by estimated fetal weight below specific 
percentile cut-offs at 35+0 to 36+6 and 31+0 to 33+6 weeks’ gestation. 
 
 
CI = confidence interval; EFW = estimated fetal weight.  
EFW cut-off Screen positive rate 
Birth at ≤ 2 weeks from assessment Birth at any time from assessment 
Detection rate 
 
Positive predictive 
value  
Detection rate 
 
Positive predictive 
value 
35+0 to 36+6 weeks n/45,847 (%; 95% CI) n/638 (%; 95% CI) % (95% CI) n/2,017 (%; 95% CI) % (95% CI) 
<3rd percentile 1,636 (3.6;  2.7-4.5) 437 (69; 65-72) 26.7 (23.7-29.7) 855 (42; 39-46) 52.2 (48.9-55.5) 
<10th percentile 4,109 (9.0; 8.7-9.3) 535 (84; 82-86) 13.0 (10.4-15.6) 1,308 (65; 62-68) 31.8 (29.8-33.8) 
<15th percentile 6,125 (13.4; 13.1-13.7) 569 (89; 87-92) 9.3 (7.1-11.6) 1,513 (75; 73-77) 24.7 (22.9-26.5) 
<20th percentile 8,089 (17.6; 17.3-17.9) 588 (92; 90-94) 7.3 (5.3-9.3) 1,630 (81; 79-83) 20.2 (18.5-21.9) 
<25th percentile 10,215 (22.3; 22.0-22.6) 608 (95; 94-97) 6.0 (4.1-7.8) 1,741 (86; 85-88) 17.0 (15.4-18.6) 
<30th percentile 12402 (27.1; 26.8-27.4) 619 (97; 96-98) 5.0 (3.3-6.7) 1,810 (90; 88-91) 14.6 (13.1-16.0) 
<35th percentile 14,694 (32.1; 31.8-32.4) 629 (99; 97-99) 4.3 (2.7-5.8) 1,867 (93; 92-94) 12.7 (11.3-14.1) 
<40th percentile 16,918 (36.9; 36.6-37.2) 632 (99; 98-100) 3.7 (2.2-5.1) 1,900 (94; 93-95) 11.2 (9.9-12.6) 
<45th percentile 19,221 (41.9; 41.6-42.2) 635 (100; 99-100) 3.3 (1.9-4.7) 1,942 (96; 96-97) 10.1 (8.8-11.4) 
<50th percentile 21,536 (47.0; 46.7-47.3) 635 (100; 99-100) 2.9 (1.6-4.2) 1,961 (97; 97-98) 9.1 (7.8-10.2) 
      
31+0 to 33+6 weeks n/21,989 (%, 95% CI) n/73 (%, 95% CI) % (95% CI) n/1,155 (%, 95% CI) % (95% CI) 
<3rd percentile 766 (3.5; 2.2-4.8) 49 (67; 58-76) 6.4 (4.7-8.0) 340 (29; 26-33) 44.4 (41.1-47.7) 
<10th percentile 2,164 (9.8; 9.4-10.2) 60 (82; 74-90) 2.8 (1.9-3.8) 603 (52; 49-55) 27.9 (25.3-30.4) 
<15th percentile 3,306 (15.0; 14.6-15.4) 64 (88; 81-94) 1.9 (1.1-2.7) 736 (64; 61-67) 22.3 (19.9-24.7) 
<20th percentile 4,459 (20.3; 19.9-20.7) 66 (90; 84-96) 1.5 (0.8-2.2) 816 (71; 68-73) 18.3 (16.1-20.5) 
<25th percentile 5,578 (25.4; 25.0-25.8) 68 (93; 88-97) 1.2 (0.6-1.8) 894 (77; 75-80) 16.0 (13.9-18.1) 
<30th percentile 6,667 (30.3; 29.9-30.7) 69 (95; 90-98) 1.0 (0.4-1.6) 954 (83; 80-85) 14.3 (12.3-16.3) 
<35th percentile 7,773 (35.3; 34.9-35.7) 71 (97; 94-98) 0.9 (0.4-1.4) 1,002 (87; 85-89) 12.9 (11.0-14.8) 
<40th percentile 8,842 (40.2; 38.8-40.6) 72 (99; 95-100) 0.8 (0.3-1.3) 1,039 (90; 88-92) 11.8 (9.9-13.7) 
<45th percentile 9,940 (45.2; 44.8-45.6) 72 (99; 95-100) 0.7 (0.2-1.2) 1,062 (92; 90-94) 10.7 (8.9-12.5) 
<50th percentile 11,035 (50.2; 49.8-50.6) 73 (100; 96-100) 0.7 (0.3-1.2) 1,081 (94; 92-95) 9.8 (8.1-11.5) 
